文献速递临床试验与 GCP流行病学与生物统计

治疗延迟对抗纤溶药在急性严重出血中疗效与安全性的影响:40 138例患者个体数据Meta分析

Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients.
PubMed 文献 · Lancet · 2017-11-07

该研究对两项大型随机试验(创伤与产后出血)的40 138例患者进行个体患者水平Meta分析,评估治疗延迟对氨甲环酸疗效的影响。总体出血死亡1 408例(40%),多数在12小时内死亡。

要点

  • 每延迟15分钟生存获益降低10%直至3小时,此后无获益。

核心结论

  • 出血死亡在起病后很快发生,即使短暂延迟治疗也会降低氨甲环酸的获益。
  • 患者必须立即接受治疗。
  • 需要进一步研究以加深对氨甲环酸作用机制的理解。

研究设计与样本

  • 对评估抗纤溶药治疗急性严重出血的、样本量超过1000例的随机试验进行个体患者水平数据Meta分析。
  • 检索1946年1月1日至2017年4月7日MEDLINE、Embase、CENTRAL、Web of Science、PubMed、Popline及WHO ICTRP。
  • 纳入两项氨甲环酸治疗急性严重出血(创伤性与产后出血)的随机试验,共40 138例患者。
  • 主要疗效指标为无出血死亡,采用逻辑回归模型检验治疗延迟对疗效的影响,并在敏感性分析中考察测量误差(错分)的影响。
  • 研究注册于PROSPERO,注册号42016052155。

主要发现

  • 共3558例死亡,其中1408例(40%)死于出血;1408例出血死亡中884例(63%)发生在起病12小时内。
  • 产后出血死亡在分娩后2-3小时达高峰。

临床怎么用

  • 对急性严重出血患者必须立即给予氨甲环酸治疗。
  • 治疗延迟会降低氨甲环酸的生存获益,应尽可能缩短给药时间。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antifibrinolytics reduce death from bleeding in trauma and post-partum haemorrhage. We examined the effect of treatment delay on the effectiveness of antifibrinolytics. METHODS: We did an individual patient-level data meta-analysis of randomised trials done with more than 1000 patients that assessed antifibrinolytics in acute severe bleeding. We identified trials done between Jan 1, 1946, and April 7, 2017, from MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, PubMed, Popline, and the WHO International Clinical Trials Registry Platform. The primary measure of treatment benefit was absence of death from bleeding. We examined the effect of treatment delay on treatment effectiveness using logistic regression models. We investigated the effect of measurement error (misclassification) in sensitivity analyses. This study is registered with PROSPERO, number 42016052155. FINDINGS: We obtained data for 40 138 patients from two randomised trials of tranexamic acid in acute severe bleeding (traumatic and post-partum haemorrhage). Overall, there were 3558 deaths, of which 1408 (40%) were from bleeding. Most (884 [63%] of 1408) bleeding deaths occurred within 12 h of onset. Deaths from post-partum haemorrhage peaked 2-3 h after childbirth. Tranexamic acid significantly increased overall survival from bleeding (odds ratio [OR] 1·20, 95% CI 1·08-1·33; p=0·001), with no heterogeneity by site of bleeding (interaction p=0·7243). Treatment delay reduced the treatment benefit (p<0·0001). Immediate treatment improved survival by more than 70% (OR 1·72, 95% CI 1·42-2·10; p<0·0001). Thereafter, the survival benefit decreased by 10% for every 15 min of treatment delay until 3 h, after which there was no benefit. There was no increase in vascular occlusive events with tranexamic acid, with no heterogeneity by site of bleeding (p=0·5956). Treatment delay did not modify the effect of tranexamic acid on vascular occlusive events. INTERPRETATION: Death from bleeding occurs soon after onset and even a short delay in treatment reduces the benefit of tranexamic acid administration. Patients must be treated immediately. Further research is needed to deepen our understanding of the mechanism of action of tranexamic acid. FUNDING: UK NIHR Health Technology Assessment programme, Pfizer, BUPA Foundation, and J P Moulton Charitable Foundation (CRASH-2 trial). London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation (WOMAN trial).

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Gayet-Ageron A, Prieto-Merino D, Ker K, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet. 2017. PMID: 29126600. doi:10.1016/S0140-6736(17)32455-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。